We are live on ! Find out more
ELOS

Syneron Medical Ltd
ELOS

Delisted

ELOS was delisted on the 14th of July, 2017.

Back to rankings

4 hedge funds and large institutions have $34.6M invested in Syneron Medical Ltd in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

85% less capital invested

Capital invested by funds: $235M → $34.6M (-$200M)

95% less funds holding

Funds holding: 79 → 4 (-75)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 73

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-75
Holders Change %
-94.94%
% of All Funds
0.1%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
–
Increased
–
Reduced
2
Closed
73
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
-$25.7M
2
GLAM
Gardner Lewis Asset Management
Pennsylvania
-$17.4M
3
AA
AQR Arbitrage
Connecticut
-$16.2M
4
KPF
K2 Principal Fund
Ontario, Canada
-$12.1M
5
FTCM
First Trust Capital Management
Illinois
-$9.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
51
Wolverine Asset Management
Illinois
– -$573K -52,382 Closed
Allianz Asset Management
52
Allianz Asset Management
Germany
– -$548K -50,000 Closed
Deutsche Bank
53
Deutsche Bank
Germany
– -$512K -46,781 Closed
EGA
54
Eagle Global Advisors
Texas
– -$494K -45,100 Closed
QI
55
QS Investors
New York
– -$369K -33,713 Closed
VF
56
Virtu Financial
New York
– -$254K -23,202 Closed
EAM
57
Exane Asset Management
France
– -$219K -20,000 Closed
FPF
58
FNY Partners Fund
New York
– -$199K -18,200 Closed
Geode Capital Management
59
Geode Capital Management
Massachusetts
– -$182K -16,633 Closed
JP Morgan Chase
60
JP Morgan Chase
New York
– -$182K -16,601 Closed
EMG
61
ETF Managers Group
New Jersey
– -$155K -14,187 Closed
TSS
62
Two Sigma Securities
New York
– -$125K -11,374 Closed
Commonwealth Equity Services
63
Commonwealth Equity Services
Massachusetts
– -$110K -10,000 Closed
Barclays
64
Barclays
United Kingdom
– -$108K -9,900 Closed
Simplex Trading
65
Simplex Trading
Illinois
– -$84.8K -7,736 Closed
PNC Financial Services Group
66
PNC Financial Services Group
Pennsylvania
– -$83K -7,466 Closed
Creative Planning
67
Creative Planning
Kansas
– -$38K -3,476 Closed
CG
68
Cutler Group
California
– -$37K -3,450 Closed
IA
69
IFP Advisors
Florida
– -$22K -2,000 Closed
UBS Group
70
UBS Group
Switzerland
– -$14K -1,250 Closed
FCMT
71
Founders Capital Management (Texas)
Texas
– -$14K -1,200 Closed
BNP Paribas Financial Markets
72
BNP Paribas Financial Markets
France
– -$10.5K -962 Closed
Wells Fargo
73
Wells Fargo
California
– -$8K -738 Closed
DADC
74
D.A. Davidson & Co
Montana
– -$5K -500 Closed
Royal Bank of Canada
75
Royal Bank of Canada
Ontario, Canada
– -$4K -400 Closed
1 2
3
4

ELOS Hedge Fund Activity: Q3 2017 in Review

4 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Syneron Medical Ltd (ELOS) for Q3 2017, worth a combined $34.6M — down 85% from $235M a quarter earlier.

Sellers outnumbered buyers: 73 funds closed out of ELOS and 0 opened new positions — a net loss of 73 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Camber Capital Management, exiting entirely with an estimated $25.7M sold.

  • 4 institutional investors held Syneron Medical Ltd (ELOS) as of Q3 2017, down from 79 in Q2 2017.
  • Funds reported $34.6M of Syneron Medical Ltd stock for Q3 2017, down 85% quarter-over-quarter.
  • 0 funds opened new Syneron Medical Ltd positions in Q3 2017 and 73 closed out, a net change of -73 holders.
  • The largest Syneron Medical Ltd seller in Q3 2017 was Camber Capital Management, an estimated $25.7M sold.

Based on aggregated 13F filings for Q3 2017.